Thus, developing potent and selective WRN helicase inhibitors and their detailed pre-clinical evaluation remains an important next step to validate the synthetic-lethal effect of WRN in MSI tumours following pharmacological inhibition. This evidence concerns the gene WRN and neoplasm.